The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies.
Because of its multi-faceted potential as a neurotrophic factor, insulin-like growth factor I (IGF-I) has been given to hundreds of ALS patients world-wide. Unlike some patients with post-polio syndrome and fragile elderly males, it is unclear whether any of these patients possess disturbances in IGF signaling. We found that about 25% of ALS patients in a controlled trial of human growth hormone (hGH) had lower or higher than normal IGF-I serum levels. Many ALS patients do have some of the characteristics of type II diabetes mellitus, where IGF-I therapy is also under way. In addition, in type I diabetes significant increase in a circulating molecule that binds IGF-I, IGF-I binding protein 1 (IGFBP-1), occurs along with reduced IGF-I, when neuropathic complications are prominent. We have studied the response of IGFBPs in ALS patients to subcutaneous rhIGF-I and found transient induction of IGFBP-1. Studies related to the IGFBPs have not been done in familial ALS (FALS) patients. However, the gene for another IGFBP, BP-2, co-localizes with the gene for juvenile ALS (ALSJ) on chromosome 2. IGF-I has been given to several models of motor neuron degeneration in the mouse, including motor neuron disease and wobbler, with beneficial effects. However, it is also not known whether any accepted genetic mouse model of motor neuron degeneration possesses any disturbance in the IGF signaling system.
Festoff
B W
BW
Neurobiology Research Laboratory (151), VA Medical Center, Kansas City, MO 64128, USA.
Yang
S X
SX
Vaught
J
J
Bryan
C
C
Ma
J Y
JY
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000503:physiopathology*; D000818:Animals; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins / Q000378:metabolism; D051379:Mice; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D013002:Somatomedins / Q000378:metabolism / Q000502:physiology* / Q000627:therapeutic use*
D018969:Insulin-Like Growth Factor Binding Proteins; D009465:Neuromuscular Agents; D013002:Somatomedins